New Report Underscores How Brand Name Drug Companies Ride High on Egregious
Pricing Practices and Anti-Competitive Tactics That Are Root Cause of High Drug
Prices in America





 



CSRxP ANALYSIS: PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS STILL 10 TIMES
GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN

New Report Underscores How Brand Name Drug Companies Ride High on Egregious
Pricing Practices and Anti-Competitive Tactics That Are Root Cause of High Drug
Prices in America



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today
released its latestanalysis
<[link removed]>
revealing that the pharmaceutical industry continues to post profit margins10
times higherthan other sectors of the prescription drug supply chain. the
updated findings confirm that Big Pharma’s entrenched pricing and patent-abuse
playbook continues to drive blockbuster profits at the expense of patients.



“Fueled by egregious pricing practices and anti-competitive tactics, Big
Pharma continues to post blockbuster profits dramatically outpacing any other
sector of the prescription drug supply chain,” said CSRxP executive director
Lauren Aronson. “By gaming the system to block competition, hiking prices at
rates outpacing inflation, and setting increasingly out-of-control launch
prices, Big Pharma continues to ride high, while too many American patients
face challenges affording their medications.”



“Brand name drug companies’ consistently posting profit margins 10 times
higher than others in the drug supply chain adds to the overwhelming evidence
that pharmaceutical industry opposition to market-based solutions to lower drug
prices is about protecting profits, not innovation, and further undermines Big
Pharma’s self-serving blame game designed to keep drug prices high,” Aronson
continued. “Policymakers must reject Big Pharma’s debunked rhetoric and hold
brand name drug companies accountable to effectively lower drug prices for
hardworking Americans.”



This latest analysis demonstrates Big Pharma’s cushy profit margin has
remained 10 times higher than other sectors of the drug supply chain,
consistent with ananalysis
<[link removed]>
conducted last year, while the industry has continued to point fingers at
others and fought market-based solutions to lower prescription drug prices,
falsely claiming they would undermine innovation into new cures.



In the new analysis, pharmaceutical manufacturers’ average annual net income
margin stands at 23.2 percent from 2017 through 2024, compared to other sectors
including distributors, retail pharmacies, pharmacy benefit managers and health
insurers. The data confirms pharmaceutical manufacturers’ lowest single-year
margin in 2017 still exceeds the highest margin of any other sector by a factor
of four.



Pharmaceutical Manufacturers’ Profit Margins are 10 Times Larger than Other
Drug Supply Chain Sectors



CSRxP’s analysis was conducted based on publicly available financial data from
company reports and filings submitted to the U.S. Securities and Exchange
Commission (SEC) for calendar years 2017 to 2024.



The full analysis can be accessed HERE
<[link removed]>
.



Read more about Big Pharma’s debunked innovation rhetoric HERE
<[link removed]>
.



Learn more about market-based solutions to hold Big Pharma accountable and
lower prescription drug pricesHERE
<[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>